Pacira BioSciences Stock Forecast
NASDAQ: PCRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 9:51 AM ET
PCRX analyst consensus
Consensus (9 analysts)
buy
Avg. price target
$30.11-17.10%
- Strong buy 1
- Buy 4
- Hold 3
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 9 Wall Street analysts covering Pacira BioSciences (2026-10-08), 5 rate the stock a buy or strong buy, 3 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $30.11, with a high estimate of $38.00 and a low estimate of $23.00. The average target implies downside of 17.1% from the current price of $36.32.
The spread between the highest and lowest targets is 65.2%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for PCRX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 11% |
| Buy | 4 | 44% |
| Hold | 3 | 33% |
| Sell | 0 | 0% |
| Strong sell | 1 | 11% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $23.00 | -36.67% |
| Average target | $30.11 | -17.10% |
| High target | $38.00 | +4.63% |